Non Invasive Prenatal Testing (NIPT) Market

Non Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021

Report Code: BT 5140 Mar, 2017, by marketsandmarkets.com

[150 Pages Report] The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016 at a CAGR of 16.4% during the forecast period. The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

Market Dynamics

Drivers

  • High risk of chromosomal abnormalities with increasing maternal age
  • Growing preference for non-invasive techniques over invasive methods
  • Launch of new and advanced products
  • Improving reimbursement scenario for NIPT
  • Programs focusing on increasing the awareness of NIPT

Restraints

  • Lack of skilled professionals

Opportunities

  • Untapped emerging markets

Challenges

  • Reliability of test results especially in obese women

High risk of chromosomal abnormalities with increasing maternal age is a major driver for the market

Maternal age refers to the age of women at the time of delivery. Advancing maternal age can result in a number of health complications, such as decreased fertility and high blood pressure, and increase in the risk of miscarriage, stillbirths, and maternal death. Moreover, advancing maternal age can increase the risk of genetic disorders in babies as a result of the improper chromosomal division. The resulting abnormalities in babies may include microcephaly; short neck; upward slanted eyes; poor muscle tone; heart, intestine, and breathing problems; and other issues.

The impact of this factor is expected to increase across the globe as a result of the increase in average age of first-time mothers. Some of the important statistics in this regard have been mentioned below:

  • In the U.S., around 10% of babies were born to first-time mothers at the age of 35 years or older, in 2016. Also, the median age of first-time mothers increased from 24.9 years in 2000 to 26.3 years in 2014 in the country (Source: CDC).
  • According to Eurostat, in 2013, around 40.6% of women in the European Union who gave birth to their first child belonged to the age group of 30 years and above. Also, in the same year, around 65,500 births of first children were reported in women aged more than 40 years.
  • According to Statistics Canada, in 2013, approximately 43% of births in the country were reported in women belonging to the age group of 30 to 49 years; in 1993, only 26% births were reported in women belonging to the same age group.
  • In Australia, the average age of first-time mothers increased from 27.8 years in 2003 to 28.6 years in 2013 (Source: Australian Bureau of Statistics, 2015).

In order to detect genetic abnormalities resulting from improper chromosomal division, there is a growing demand for developing advanced and effective diagnostic procedures for early screening. Non-invasive prenatal testing is one such upcoming field which utilizes cell-free DNA in maternal plasma/fetal cells in maternal blood to determine genetic abnormalities. Thus, with the growing incidence of chromosomal abnormalities and benefits offered by NIPT, the demand for these tests is expected to increase in the coming years.

The tables mentioned below provide statistics for the incidence rate of trisomies and indicate the impact of the increase in maternal age on the growth in risk of Down syndrome

Non-Invasive Prenatal Testing (NIPT) Market

To know about the assumptions considered for the study, download the pdf brochure

The following are the major objectives of the study:

  • To define, describe, and forecast the global non-invasive prenatal testing (NIPT) market on the basis of product, method, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for the market leaders
  • To forecast the size of the market with respect to four regions, namely, North America, Europe, Asia, and the Rest of the World
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
  • To track and analyze competitive developments such as agreements, collaborations, partnerships, product launches, acquisitions, expansions, and other developments in the NIPT market

During this research study, major players operating in the NIPT market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

Non-Invasive Prenatal Testing (NIPT) Market

The NIPT market is competitive in nature, with several major players competing for market space. Some of the prominent players in the market include  Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), Beijing Genomics Institute (China), GE Healthcare (U.S.), and Koninklijke Philips N.V. (Netherlands).

Major Market Developments:

  • In January 2017, Pacific Biosciences California, Inc. signed an agreement to supply Novogene Corporation, a provider of genomic and bioinformatics solutions, with ten sequel Systems for whole genome sequencing, Iso-sequence annotation, and target sequencing services
  • In November 2016, GE Healthcare launched its ultrasound system—LOGIQ E9 XDclear 2.0 and showcased 25 new products at the Radiological Society of North America (RSNA) (U.S.). The showcased products included Senographe Pristina, SIGNA, DiscoveryMI and GSI Xtream on Revolution CT2, OptimaXR240amx, and other digital and software technologies. These products offer improved performance, productivity, and better clinical outcomes for clinicians and hospitals worldwide.
  • In March 2016, Thermo Fisher Scientific acquired Affymetrix, Inc. (U.S.), a leading provider of life science and molecular diagnostic products. This acquisition enabled the company to strengthen its bioscience and genetic analysis capabilities.

Market Audience:

  • Diagnostic laboratories
  • Hospitals
  • Medical research institutes
  • Market research and consulting firms
  • Venture capitalists
  • NIPT product manufacturers
  • Suppliers and distributors of NIPT instruments

Scope of the Report:

Non-invasive Prenatal Testing Market, by Product

  • Consumables
  • Assay Kits &Reagents
  • Disposables
  • Instruments
  • NGS Systems
  • PCR Instruments
  • Microarrays
  • Ultrasound Devices
  • Other Instruments

Note: Other instruments include centrifuges, UV systems, incubators, and microscopes.

Non-invasive Prenatal Testing Market, by Method

  • Ultrasound Detection
  • Biochemical Screening tests
  • Cell-free DNA in Maternal Plasma Tests
  • Fetal Cells in Maternal Blood Tests

Non-invasive Prenatal Testing Market, by Application

  • Trisomy
  • Microdeletion Syndrome
  • Other Applications

Note: Others applications include Monogenic disorders, Klinefelter syndrome, Gender detection, and rhesus (Rh) blood type.

Non-invasive Prenatal Testing Market, by End User

  • Diagnostic Laboratories
  • Hospitals

Non-invasive Prenatal Testing Market, by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • RoE
  • Asia
  • Rest of the World (RoW)

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.
The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to 5)

The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021. The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

The market in this report is segmented on the basis of product, method, application, end user, and region. Based on product, the market is segmented into consumables and instruments. The consumable segment is further divided into assay kits & reagents and disposables. The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT.

Based on method, the market is further divided into ultrasound detection, biochemical screening tests, fetal cells in maternal blood tests, and cell-free DNA in maternal plasma tests. In 2016, the ultrasound detection accounted for the largest share of the market. However, the cell-free DNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period. This is mainly attributed to the increasing demand for cf-DNA based techniques in NIPT testing and rising government initiatives to provide prenatal services.

Based on application, the market is divided into Trisomy, microdeletion syndrome, and other applications. Trisomy forms the largest and fastest-growing application segment of the global market. This is mainly attributed to the rising incidence of chromosomal abnormalities with increasing maternal age.

Based on end user, the market is segmented into diagnostic laboratories and hospitals. In 2016, the diagnostic laboratories segment accounted for the largest share of the market. Growth in this end-user segment can be attributed to the rising incidence of chromosomal abnormalities and increasing initiatives by companies to provide advanced products in NIPT to diagnostic laboratories.

Non-Invasive Prenatal Testing (NIPT) Market

Cell-Free DNA in Maternal Plasma Tests Segment form the Fastest Growing Segment in NIPT Market, by Method

Ultrasound Detection

Ultrasound detection is a routine procedure performed throughout pregnancy for evaluating the health and development of the fetus. It is the most widely used non-invasive method for monitoring the health of the fetus. Ultrasound scans provide real-time images showing the movement and external features of the fetus; they can also help identify genetic abnormalities in the fetus. This test is conducted between 11 to 13 weeks of gestation.

Biochemical Screening Tests

Biochemical screening tests are used to indicate the presence of some biological compounds present in maternal blood. These tests include biochemical markers used to diagnose fetal chromosomal abnormalities such as Down syndrome.

Cell-Free DNA in Maternal Plasma Tests

Maternal plasma is a mixture of maternal and fetal blood that comprises fetal DNA in minor amounts. This fetal DNA can be used for the detection of aneuploidies and other abnormalities. This test can be performed as early as 10 weeks of gestation

Fetal Cells in Maternal Blood Tests

In 2016, the FCMB (fetal cells in maternal blood) tests segment is estimated to account for a share of 12.0% of the NIPT market. This segment is projected to reach USD 375.0 million by 2021 from USD 161.6 million in 2016, at a CAGR of 18.3% during the forecast period. The growth in this segment is mainly driven by technological advancements in the isolation of fetal cells for prenatal testing

Critical questions the report answers:

  • Where will all these developments take the industry in the mid to long term?
  • Emerging countries have immense opportunities for the growth of NIPT product manufacturers, will this scenario continue?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Lack of skilled professionals, and reliability of test results especially in obese women are major factors restraining the growth of the market. Some of the prominent players in the market include GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Table of Contents

1 Introduction (Page No. - 16)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 19)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Assumptions for the Study

3 Executive Summary (Page No. - 26)

4 Premium Insights (Page No. - 30)
    4.1 Non-Invasive Prenatal Testing Market: Overview
    4.2 NIPT Consumables Market Size, By Type, 2016 vs 2021 (USD Million)
    4.3 NIPT Instruments Market Size, By Type, 2016 vs 2021 (USD Million)
    4.4 Geographic Analysis: Market, By Method (2016)
    4.5 NIPT Market, By Application (2016–2021)
    4.6 Non-Invasive Prenatal Testing Market Size, By End User, 2016 vs 2021 (USD Million)
    4.7 Geographic Snapshot (2016–2021)

5 Market Overview (Page No. - 34)
    5.1 Introduction
           5.1.1 Drivers
                    5.1.1.1 High Risk of Chromosomal Abnormalities With Increasing Maternal Age
                    5.1.1.2 Growing Preference for Non-Invasive Techniques Over Invasive Methods
                    5.1.1.3 Launch of New and Advanced Products
                    5.1.1.4 Improving Reimbursement Scenario for NIPT
                    5.1.1.5 Programs Focusing on Increasing the Awareness of NIPT
           5.1.2 Restraint
                    5.1.2.1 Lack of Skilled Professionals
           5.1.3 Opportunity
                    5.1.3.1 Untapped Emerging Markets
           5.1.4 Challenge
                    5.1.4.1 Reliability of Test Results Especially in Obese Women

6 Non-Invasive Prenatal Testing Market, By Product (Page No. - 41)
    6.1 Introduction
    6.2 Consumables
           6.2.1 Assay Kits & Reagents
           6.2.2 Disposables
    6.3 Instruments
           6.3.1 Ultrasound Devices
           6.3.2 Next-Generation Sequencing Systems
           6.3.3 Polymerase Chain Reaction Instruments
           6.3.4 Microarrays
           6.3.5 Other Instruments

7 Non-Invasive Prenatal Testing Market, By Method (Page No. - 52)
    7.1 Introduction
    7.2 Ultrasound Detection
    7.3 Biochemical Screening Tests
    7.4 Cell-Free Dna in Maternal Plasma Tests
    7.5 Fetal Cells in Maternal Blood Tests

8 Non-Invasive Prenatal Testing Market, By Application (Page No. - 62)
    8.1 Introduction
    8.2 Trisomy
    8.3 Microdeletion Syndrome
    8.4 Other Applications

9 Non-Invasive Prenatal Testing Market, By End User (Page No. - 69)
    9.1 Introduction
    9.2 Diagnostic Laboratories
    9.3 Hospitals

10 Non-Invasive Prenatal Testing Market, By Region (Page No. - 75)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
             10.3.1 Germany
             10.3.2 France
             10.3.3 U.K.
             10.3.4 Rest of Europe (RoE)
     10.4 Asia
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 104)
     11.1 Overview
     11.2 Market Analysis
     11.3 Competitive Situation and Trends
             11.3.1 Partnerships, Collaborations, & Agreements
             11.3.2 Product Launches
             11.3.3 Acquisitions
             11.3.4 Expansions
             11.3.5 Other Strategies

12 Company Profile (Page No. - 112)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
     12.1 Introduction
     12.2 Ge Healthcare (A Wholly Owned Subsidiary of General Electric Company)
     12.3 Koninklijke Philips N.V.
     12.4 Illumina, Inc.
     12.5 Thermo Fisher Scientific, Inc.
     12.6 F. Hoffman-La Roche Ltd.
     12.7 Pacific Biosciences of California, Inc.
     12.8 Perkinelmer, Inc.
     12.9 Qiagen N.V.
     12.10 Agilent Technologies, Inc.
     12.11 Beijing Genomics Institute

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 141)
     13.1 Insights From Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details


List of Tables (110 Tables)

Table 1 Incidence Rate of Trisomies
Table 2 Risk of Down Syndrome With Increasing Maternal Age
Table 3 Comparison of Non-Invasive and Invasive Prenatal Testing
Table 4 NIPT Reimbursement Scenario, By Country
Table 5 Public Healthcare Expenditure (% of GDP)
Table 6 Global Non-Invasive Prenatal Testing Market Size, By Product, 2014–2021 (USD Million)
Table 7 Global NIPT Consumables Market Size, By Type, 2014–2021 (USD Million)
Table 8 Global NIPT Consumables Market Size, By Region, 2014–2021 (USD Million)
Table 9 North America: NIPT Consumables Market Size, By Country, 2014–2021 (USD Million)
Table 10 Europe: NIPT Consumables Market Size, By Country, 2014–2021 (USD Million)
Table 11 Global NIPT Assay Kits and Reagents Market Size, By Region, 2014–2021 (USD Million)
Table 12 Global NIPT Disposables Market Size, By Region, 2014–2021 (USD Million)
Table 13 Global NIPT Instruments Market Size, By Type, 2014–2021 (USD Million)
Table 14 Global NIPT Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 15 North America: NIPT Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 16 Europe: NIPT Instruments Market Size, By Country, 2014–2021 (USD Million)
Table 17 Global NIPT Ultrasound Devices Market Size, By Region, 2014–2021 (USD Million)
Table 18 Global NIPT Next-Generation Sequencing Systems Market Size, By Region, 2014–2021 (USD Million)
Table 19 Global NIPT Pcr Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 20 Global NIPT Microarrays Market Size, By Region, 2014–2021 (USD Million)
Table 21 Other NIPT Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 22 Global Non-Invasive Prenatal Testing Market Size, By Method, 2014-2021 (USD Million)
Table 23 Global Market Size for Ultrasound Detection, By Region, 2014-2021 (USD Million)
Table 24 North America: Market Size for Ultrasound Detection, By Country, 2014-2021 (USD Million)
Table 25 Europe: NIPT Market Size for Ultrasound Detection, By Country, 2014-2021 (USD Million)
Table 26 Global Non-Invasive Prenatal Testing Market Size for Biochemical Screening Tests, By Region, 2014-2021 (USD Million)
Table 27 North America: Market Size for Biochemical Screening Tests, By Country, 2014-2021 (USD Million)
Table 28 Europe: Market Size for Biochemical Screening Tests, By Country, 2014-2021 (USD Million)
Table 29 Global Market Size for Cfdna in Maternal Plasma Tests, By Region, 2014-2021 (USD Million)
Table 30 North America: NIPT Market Size for Cfdna in Maternal Plasma Tests, By Country, 2014-2021 (USD Million)
Table 31 Europe: NIPT Market Size for Cfdna in Maternal Plasma Tests, By Country, 2014-2021 (USD Million)
Table 32 Global Non-Invasive Prenatal Testing Market Size for Fcmb Tests, By Region, 2014-2021 (USD Million)
Table 33 North America: Market Size for Fcmb Tests, By Country, 2014-2021 (USD Million)
Table 34 Europe: Market Size for Fcmb Tests, By Country, 2014-2021 (USD Million)
Table 35 NIPT Market Size, By Application, 2014-2021 (USD Million)
Table 36 Non-Invasive Prenatal Testing Market Size for Trisomy, By Region, 2014-2021 (USD Million)
Table 37 North America: Market Size for Trisomy, By Country, 2014-2021 (USD Million)
Table 38 Europe: NIPT Market Size for Trisomy, By Country, 2014-2021 (USD Million)
Table 39 NIPT Market Size for Microdeletion Syndrome, By Region, 2014-2021 (USD Million)
Table 40 North America: Non-Invasive Prenatal Testing Market Size for Microdeletion Syndrome, By Country, 2014-2021 (USD Million)
Table 41 Europe: Non-Invasive Prenatal Testing Market Size Microdeletion Syndrome, By Country, 2014-2021 (USD Million)
Table 42 Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 43 North America: Market Size for Other Applications, By Country, 2014-2021 (USD Million)
Table 44 Europe: Market Size for Other Applications, By Country, 2014-2021 (USD Million)
Table 45 Non-Invasive Prenatal Testing Market Size, By End User, 2014–2021 (USD Million)
Table 46 NIPT Market Size for Diagnostic Laboratories, By Region, 2014–2021 (USD Million)
Table 47 North America: NIPT Market Size for Diagnostic Laboratories, By Country, 2014–2021 (USD Million)
Table 48 Europe: Non-Invasive Prenatal Testing Market Size for Diagnostic Laboratories, By Country, 2014–2021 (USD Million)
Table 49 Market Size for Hospitals, By Region, 2014–2021 (USD Million)
Table 50 North America: Market Size for Hospitals, By Country, 2014–2021 (USD Million)
Table 51 Europe: Non-Invasive Prenatal Testing Market Size for Hospitals, By Country, 2014–2021 (USD Million)
Table 52 NIPT Market Size, By Region, 2014-2021 (USD Million)
Table 53 North America: Non-Invasive Prenatal Testing Market Size, By Product, 2014-2021 (USD Million)
Table 54 North America: Testing Consumables Market Size, By Type, 2014-2021 (USD Million)
Table 55 North America: NIPT Instruments Market Size, By Type, 2014-2021 (USD Million)
Table 56 North America: Market Size, By Method, 2014-2021 (USD Million)
Table 57 North America: Market Size, By Application, 2014-2021 (USD Million)
Table 58 North America: Market Size, By End User, 2014-2021 (USD Million)
Table 59 North America: Market Size, By Country, 2014-2021 (USD Million)
Table 60 U.S.: Non-Invasive Prenatal Testing Market Size, By Product, 2014-2021 (USD Million)
Table 61 U.S.: Market Size, By Method, 2014-2021 (USD Million)
Table 62 U.S.: Market Size, By Application, 2014-2021 (USD Million)
Table 63 U.S.: NIPT Market Size, By End User, 2014-2021 (USD Million)
Table 64 Canada: Non-Invasive Prenatal Testing Market Size, By Product, 2014-2021 (USD Million)
Table 65 Canada: Testing Market Size, By Method, 2014-2021 (USD Million)
Table 66 Canada: Testing Market Size, By Application, 2014-2021 (USD Million)
Table 67 Canada: NIPT Market Size, By End User, 2014-2021 (USD Million)
Table 68 Europe: Non-Invasive Prenatal Testing Market Size, By Country, 2014-2021 (USD Million)
Table 69 Europe: Market Size, By Product, 2014-2021 (USD Million)
Table 70 Europe: Consumables Market Size, By Type, 2014-2021 (USD Million)
Table 71 Europe: Non-Invasive Prenatal Testing Instruments Market Size, By Type, 2014-2021 (USD Million)
Table 72 Europe: Market Size, By Method, 2014-2021 (USD Million)
Table 73 Europe: Market Size, By Application, 2014-2021 (USD Million)
Table 74 Europe: NIPT Market Size, By End User, 2014-2021 (USD Million)
Table 75 Germany: Non-Invasive Prenatal Testing Market Size, By Product, 2014-2021 (USD Million)
Table 76 Germany: Market Size, By Method, 2014-2021 (USD Million)
Table 77 Germany: Market Size, By Application, 2014-2021 (USD Million)
Table 78 Germany: Testing Market Size, By End User, 2014-2021 (USD Million)
Table 79 France: Non-Invasive Prenatal Testing Market Size, By Product, 2014-2021 (USD Million)
Table 80 France: Market Size, By Method, 2014-2021 (USD Million)
Table 81 France: Market Size, By Application, 2014-2021 (USD Million)
Table 82 France: Market Size, By End User, 2014-2021 (USD Million)
Table 83 U.K.: Non-Invasive Prenatal Testing Market Size, By Product, 2014-2021(USD Million)
Table 84 U.K.: Market Size, By Method, 2014-2021(USD Million)
Table 85 U.K.: NIPT Market Size, By Application, 2014-2021 (USD Million)
Table 86 U.K.: Testing Market Size, By End User, 2014-2021 (USD Million)
Table 87 RoE: Market Size, By Product, 2014-2021 (USD Million)
Table 88 RoE: Market Size, By Method, 2014-2021 (USD Million)
Table 89 RoE: Market Size, By Application, 2014-2021 (USD Million)
Table 90 RoE: Non-Invasive Prenatal Testing Market Size, By End User, 2014-2021 (USD Million)
Table 91 Asia: Market Size, By Product, 2014-2021 (USD Million)
Table 92 Asia: Consumables Market Size, By Type, 2014-2021 (USD Million)
Table 93 Asia: Instruments Market Size, By Type, 2014-2021 (USD Million)
Table 94 Asia: Market Size, By Method, 2014-2021 (USD Million)
Table 95 Asia: Non-Invasive Prenatal Testing Market Size, By Application, 2014-2021 (USD Million)
Table 96 Asia: Market Size, By End User, 2014-2021 (USD Million)
Table 97 RoW: Market Size, By Product, 2014-2021 (USD Million)
Table 98 RoW: NIPT Consumables Market Size, By Type, 2014-2021 (USD Million)
Table 99 RoW: Instruments Market Size, By Type, 2014-2021 (USD Million)
Table 100 RoW: Non-Invasive Prenatal Testing Market Size, By Method, 2014-2021 (USD Million)
Table 101 RoW: NIPT Market Size, By Application, 2014-2021 (USD Million)
Table 102 RoW: Market Size, By End User, 2014-2021 (USD Million)
Table 103 Market Ranking, By Key Player, 2015
Table 104 Partnerships, Collaborations, & Agreements (2014-2017)
Table 105 Product Launches (2014–2017)
Table 106 Acquisitions (2014–2017)
Table 107 Expansions (2014–2017)
Table 108 Other Strategies (2014–2017)
Table 109 Exchange Rate (Used for the Conversion of Euro to USD)
Table 110 Exchange Rate (Used for the Conversion of CHF to USD)


List of Figures (48 Figures)

Figure 1 Non-Invasive Prenatal Testing Market Segmentation
Figure 2 Research Design
Figure 3 Market Size Estimation: Bottom-Up Approach
Figure 4 Market Size Estimation: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Key Data From Secondary Sources
Figure 8 Key Data From Primary Sources
Figure 9 Non-Invasive Prenatal Testing Market, By Method, 2016 vs 2021 (USD Million)
Figure 10 Market, By Product, 2016 vs 2021 (USD Million)
Figure 11 NIPT Market, By Application, 2016 vs 2021 (USD Million)
Figure 12 Non-Invasive Prenatal Testing Market, By End User, 2016 vs 2021 (USD Million)
Figure 13 North America Dominated the Global NIPT Market in 2016
Figure 14 High Risk of Chromosomal Abnormality Associated With Increasing Maternal Age is Driving the Market Growth for Non-Invasive Prenatal Testing
Figure 15 Assay Kits & Reagents Dominated the NIPT Consumables Market in 2016
Figure 16 NGS Systems to Register the Highest CAGR in the NIPT Instruments Market From 2016 to 2021
Figure 17 Ultrasound Detection Commanded the Largest Share of the Market in 2016
Figure 18 Trisomy Was the Largest Application Segment in the Market in 2016
Figure 19 Diagnostic Laboratories Dominated the Non-Invasive Prenatal Testing Market in 2016
Figure 20 Asia to Register the Highest Growth During the Forecast Period
Figure 21 NIPT Market: Drivers, Restraints, Opportunities, and Challenges
Figure 22 Non-Invasive Prenatal Testing Market Segmentation, By Product
Figure 23 Consumables to Dominate the Market During the Forecast Period
Figure 24 Cfdna in Maternal Plasma Tests to Grow at the Highest CAGR During the Forecast Period
Figure 25 North America to Dominate the Market During Forecast Period
Figure 26 Asia to Witness Highest Growth in the Biochemical Screening Tests Market During 2016–2021
Figure 27 Asia to Witness Highest Growth During the Forecast Period
Figure 28 North America to Dominate the Fcmb Tests Market During the Forecast Period
Figure 29 Trisomy to Dominate the NIPT Market, By Application, During the Forecast Period
Figure 30 Diagnostic Laboratories Dominated the Non-Invasive Prenatal Testing End-User Market in 2016
Figure 31 North America to Dominate the Market During the Forecast Period
Figure 32 North America: Non-Invasive Prenatal Testing Market Snapshot
Figure 33 Europe: Market Snapshot
Figure 34 Asia: NIPT Market Snapshot
Figure 35 RoW: Market Snapshot
Figure 36 Key Players Adopted Organic as Well as Inorganic Growth Strategies Between 2014 and 2016
Figure 37 Market Evolution Framework
Figure 38 Battle for Market Share: Agreements, Collaborations, and Partnerships Was the Key Strategy Adopted By Market Players
Figure 39 Product Mix of the Top Players in the NIPT Market
Figure 40 General Electric Company: Company Snapshot (2015)
Figure 41 Koninklijke Philips N.V.: Company Snapshot (2016)
Figure 42 Illumina, Inc.: Company Snapshot (2016)
Figure 43 Thermo Fisher Scientific, Inc.: Company Snapshot (2016)
Figure 44 F. Hoffmann-La Roche Ltd: Company Snapshot (2016)
Figure 45 Pacific Biosciences of California, Inc.: Company Snapshot (2016)
Figure 46 Perkinelmer, Inc.: Company Snapshot (2016)
Figure 47 Qiagen N.V.: Company Snapshot (2016)
Figure 48 Agilent Technologies, Inc.: Company Snapshot (2016)


    Request for detailed methodology, assumptions & how numbers were triangulated.

    Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
    • Select all
    • News-Letters with latest Market insights
    • Information & discussion on the relevant new products and services
    • Information & discussion on Market insights and Market information
    • Information & discussion on our events and conferences
      • Select all
      • Email Phone Professional and social network (Linkedin, etc)
    Report Code
    BT 5140
    Published ON
    Mar, 2017
    Choose License Type
    BUY NOW
    • SHARE
    X
    Request Customization
    Speak to Analyst
    Speak to Analyst
    OR FACE-TO-FACE MEETING
    PERSONALIZE THIS RESEARCH
    • Triangulate with your Own Data
    • Get Data as per your Format and Definition
    • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
    • Any level of Personalization
    REQUEST A FREE CUSTOMIZATION
    LET US HELP YOU!
    • What are the Known and Unknown Adjacencies Impacting the Non Invasive Prenatal Testing (NIPT) Market
    • What will your New Revenue Sources be?
    • Who will be your Top Customer; what will make them switch?
    • Defend your Market Share or Win Competitors
    • Get a Scorecard for Target Partners
    REQUEST A FREE WORKSHOP
    ADJACENT MARKETS
    REQUEST BUNDLE REPORTS
    ONLINE CHAT
    +1-888-600-6441
    • Call Us
    • +1-888-600-6441 (Corporate office hours)
    • +1-888-600-6441 (US/Can toll free)
    • +44-800-368-9399 (UK office hours)
    CONNECT WITH US
    ABOUT TRUST ONLINE
    © MarketsandMarkets Research Private Ltd. All rights reserved